Rx Fraud Cases: Beat Goes On As Whistleblowers Pursue Lesser Allegations
Executive Summary
“There are enough layoffs out there that there is this walking group of disaffected people who are continuing to file qui tams, whether those are valid or not,” Boston Assistant U.S. Attorney Susan Winkler says. A Pfizer attorney suggests proactive steps to protect corporate leaders from prosecution.
You may also be interested in...
Pharma Under The Gun: FDA And DoJ Use Tough Tactics In Investigations
Former government attorneys offer advice on how companies can respond to government search warrants and fake identities; current prosecutors discuss the tools they use and the kinds of cases they are pursuing.
The Era Of Billion Dollar Pharma Settlements
Abbott Laboratories is the third pharmaceutical company to reach a settlement with the Department of Justice in excess of $1 billion. A look at the deals struck since Eli Lilly began the billion dollar club in 2009 shows the activities the government is investigating and the level of liability that companies face.
User Fee Legislation Revs Through Senate Mark-up, But House Bill Goes Back Into The Shop
Senate health committee defers action on several potentially contentious issues, with members hoping to resolve differences over FDA’s authorities on imports, shortages, foreign data and track-and-trace before the bill goes to the floor, possibly in May. Meanwhile, the House postpones its mark-up in an effort to craft a more bipartisan bill, and now will try to push the user fee package to the floor during an upcoming four-day marathon session.